Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2017

Klempner Samuel J, Borghei Ali, Hakimian Behrooz, Ali Siraj M, Ou Sai-Hong Ignatius

Abstract excerpt

INTRODUCTION: A significant portion of NSCLCs with MET proto-oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping alterations are sensitive to small-molecule mesenchymal-epithelial transition tyrosine kinase inhibitors. However, the incidence and management of brain metastases in this molecular subset is unknown and represents an unmet clinical need. METHODS: Hybrid capture-based comprehensive genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-met

Share to Pyridines

Source

Identifiers

PMID: 27693535
DOI: 10.1016/j.jtho.2016.09.127

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.PMID 27693535Read ↗

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read ↗

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.Semantic proximity Read ↗

Sequencing brain metastases and opportunities for targeted therapies.Semantic proximity Read ↗

Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Semantic proximity Read ↗

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.Semantic proximity Read ↗

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.Semantic proximity Read ↗

Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.Semantic proximity Read ↗

Targeted Therapy in Brain Metastases: Ready for Primetime?Semantic proximity Read ↗

MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.Semantic proximity Read ↗

CNS Metastases in Patients With Non–Small-Cell Lung Cancer and <i>ALK</i> Gene RearrangementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.